Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins

Journal of the American College of Cardiology

Volumn 65, Issue 21, 2015, Pages 2267-2275

  Schwartz, Gregory G ^a   Abt, Markus ^b   Bao, Weihang ^c   Demicco, David ^c   Kallend, David ^b   Miller, Michael ^d   Mundl, Hardi ^b   Olsson, Anders G ^e,f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c PFIZER INC   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Stockholm Heart Center   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

lipids; myocardial infarction; unstable angina

Indexed keywords

ATORVASTATIN; DALCETRAPIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DIET RESTRICTION; FEMALE; HEART DEATH; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FASTING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 84930025596     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.544     Document Type: Article

References (30)

1. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
2. G.G. Schwartz, A.G. Olsson, M. Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
3. C.P. Cannon, E. Braunwald, C.H. McCabe for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
4. T. Nakamura, and K. Kugiyama Triglycerides and remnant particles as risk factors for coronary artery disease Curr Atheroscler Rep 8 2006 107 110
5. Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
6. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
7. B.G. Nordestgaard, M. Benn, and P. Schnohr Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
8. N. Sarwar, J. Danesh, and G. Eiriksdottir Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
9. E. Bruckert, J. Labreuche, and D. Deplanque Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis J Cardiovasc Pharmacol 57 2011 267 272
10. F.M. Sacks, P. Alaupovic, and L.A. Moye VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 2000 1886 1892
11. M. Miller, C.P. Cannon, S.A. Murphy for the PROVE IT-TIMI 22 Investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
12. O. Faergeman, I. Holme, R. Fayyad for the Steering Committees of IDEAL and TNT Trials Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease Am J Cardiol 104 2009 459 463
13. A. Varbo, M. Benn, and A. Tybjaerg-Hansen Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
14. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
15. A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 2014 32 41
16. S.J. Nicholls, J.J. Kastelein, G.G. Schwartz for the VISTA-16 Investigators Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial JAMA 311 2014 252 262
17. M. Yokoyama, H. Origasa, M. Matsuzaki for the Japan EPA Lipid Intervention Study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
18. G.G. Schwartz, M.F. Oliver, and M.D. Ezekowitz Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction Am J Cardiol 81 1998 578 581
19. G.G. Schwartz, A.G. Olsson, C.M. Ballantyne for the dal-OUTCOMES Committees and Investigators Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 2009 896 901
20. M.J. Caslake, G. Stewart, and S.P. Day Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia Atherosclerosis 171 2003 245 253
21. M. Miller, N.J. Stone, C. Ballantyne American Heart Association Clinical Lipidology Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
22. S.M. Grundy, H. Arai, and P. Barter An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary Atherosclerosis 232 2014 410 413
23. P.J. Barter, and K.A. Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J Lipid Res 53 2012 1755 1766
24. A. Mazza, V. Tikhonoff, and L. Schiavon Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly Intern Med J 35 2005 604 610
25. C. Kragelund, O. Snorgaard, and L. Kober Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients Eur Heart J 25 2004 1891 1897
26. S. Bansal, J.E. Buring, and N. Rifai Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
27. S.S. Martin, M.J. Blaha, and M.B. Elshazly Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications J Am Coll Cardiol 62 2013 732 739
28. C.M. Ballantyne, R.A. Braeckman, and P.N. Soni Icosapent ethyl for the treatment of hypertriglyceridemia Expert Opin Pharmacother 14 2013 1409 1416
29. M.J. Graham, R.G. Lee, and T.A. Bell 3rd Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490
30. E.A. Stein, R.P. Giugliano, and M.J. Koren Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J 35 2014 2249 2259